Hologic, Inc.’s Stock Price Dips to $68.75, Recording a 2.07% Decrease: An Insight into HOLX’s Market Performance

Hologic, Inc. (HOLX)

68.75 USD -1.45 (-2.07%) Volume: 3.92M

Hologic, Inc.’s stock price stands at 68.75 USD, experiencing a decrease of -2.07% in the latest trading session with a volume of 3.92M, and marking a -4.63% change Year-To-Date, reflecting the company’s dynamic market performance.

Latest developments on Hologic, Inc.

Marlborough-based medical device maker, Hologic Inc, has been facing a series of challenges recently, with the company receiving an FDA warning over its implantable devices. Despite this, Benson Investment Management Company Inc. has made a new investment in the company, showing confidence in its long-term prospects. Hologic’s stock has hit a new 52-week low amidst market shifts and underperformed compared to its competitors. However, analysts at Needham & Company LLC have reaffirmed a buy rating for the stock, emphasizing its potential for growth. With Hologic announcing board changes ahead of its 2025 Annual Meeting and an expected strong Q1 EPS, investors are closely watching how the stock will play out in the coming days.

Hologic, Inc. on Smartkarma

Analysts at Baptista Research have been closely following Hologic Inc‘s recent financial performance and strategic moves. In their report titled “Hologic Inc.: Expanding Diagnostic Assay Portfolio For A Competitive Edge! – Major Drivers,” the analysts highlight the company’s fourth-quarter results for fiscal year 2024. Hologic reported a total revenue of $987.9 million in the fourth quarter, showing a 4.2% increase year-over-year. The organic revenue growth, excluding COVID-related sales, was 5%. Additionally, the non-GAAP earnings per share (EPS) grew by 13.5% to $1.01, indicating positive momentum for the company.

Another report by Baptista Research, titled “Hologic Inc.: Breast Health Innovations,” focuses on the company’s strong performance in the third quarter of fiscal 2024. Despite challenges posed by the pandemic and global disruptions like the chip shortage, Hologic demonstrated resilience and strategic efficiency. The company reported a total revenue of $1.01 billion and a non-GAAP earnings per share of $1.06, surpassing their guidance predictions. This marked a 3.1% increase in revenue compared to the previous year, signaling a solid recovery trajectory for Hologic Inc.

A look at Hologic, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Hologic Inc has a mixed long-term outlook. While the company scores moderately in terms of value, resilience, and momentum, its scores for dividend and growth are lower. This suggests that Hologic may not be the most attractive option for investors seeking high dividends or significant growth potential. However, the company’s strong performance in value, resilience, and momentum factors indicate that it may still offer stability and potential for long-term growth in the diagnostic products and medical imaging industry.

Hologic, Inc. is a developer, manufacturer, and supplier of premium diagnostic products, medical imaging systems, and surgical products. The company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a diverse range of products and a focus on cutting-edge technology, Hologic aims to provide innovative solutions for healthcare professionals and patients alike. While the company’s Smart Scores vary across different factors, its overall outlook suggests a solid foundation in the industry with room for continued growth and success.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma